An Open-Label, Multicenter, Nonrandomized, Dose-Escalation, and Tumor-Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat (INCB024360), With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs CB 1158 (Primary) ; Epacadostat (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 13 Mar 2018 Planned number of patients changed from 190 to 389.
- 13 Mar 2018 Status changed from not yet recruiting to recruiting.
- 12 Dec 2017 New trial record